Replimune Group Inc. (REPL) — Research Summary as of 2026-08-03

Key Recent Catalysts (Last ~1–3 Months)

FDA Advisory Committee Vote (Late July 2026)

The most significant recent catalyst was the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (AdCom) vote in late July 2026. The panel voted 10-3 that efficacy results from the single-arm IGNYTE trial of RP1 (with nivolumab) supported approval for advanced melanoma [1][4]. This favorable vote backed Replimune's Biologics License Application (BLA) resubmission and was seen as signaling "a more constructive regulatory view," boosting odds of eventual full FDA approval [2]. The stock surged dramatically following this news, trading up 132.9% [4].